ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 11, 2005--Celera Diagnostics, a joint venture between the Applied Biosystems Group (NYSE:ABI) and Celera Genomics Group (NYSE:CRA) of Applera Corporation, today announced that it will present data on its fragile X research assay at the Association for Molecular Pathology’s 11th Annual Meeting, from November 11-13, 2005, in Scottsdale, Arizona. This study shows results for amplification of normal and pre-mutation triplet repeats in the FMR1 (fragile X mental retardation) gene and sizing them on the ABI PRISM(R) 3100 and 3130 Genetic Analyzers. Also included is amplification of a novel gender gene that can be used to determine whether females have two normal copies of the repeats.
